June 7, 2022
Advisers to the U.S. Food and Drug Administration on Tuesday will consider whether to recommend Novavax Inc’s COVID-19 vaccine for adults, which the drugmaker hopes can become the shot of choice among some American vaccine skeptics.
Novavax’s shot is a more traditional type of vaccine employing technology that has been used for decades to combat diseases including Hepatitis B and influenza.
The company is hoping to gain a foothold within the less than one-quarter of U.S. adults who have yet to be vaccinated, particularly those who do not want to receive a vaccine like the Pfizer/BioNTech or Moderna Inc shots based on groundbreaking messenger RNA (mRNA) technology.
“There are still a substantial number of people that are not yet vaccinated,” Novavax Chief Commercial Officer John Trizzino said in a media briefing late last month.
“I think we’ll see uptake in those people that have either been vaccine hesitant or have a preference for something other than mRNA vaccine.”
